Loading...
•
Dec 31, 2023
Cabaletta Bio Q4 2023 Earnings Report
Cabaletta Bio reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
Key Takeaways
Cabaletta Bio reported its Q4 and full year 2023 financial results. The company's cash, cash equivalents, and short-term investments totaled $241.2 million as of December 31, 2023, which is expected to fund operations into the first half of 2026. The first patient has been dosed with CABA-201 in the RESET™ clinical trial program.
First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program
Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24
RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24
Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile dermatomyositis
Forward Guidance
Cabaletta Bio expects that its cash, cash equivalents and short-term investments as of December 31, 2023, will enable it to fund its operating plan into the first half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...